FUNDAMENTALS
EdgeFII/DII
MANKINDMankind Pharma
₹2,665.00+1.37%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
MANKINDNSE · EquityPharmaceuticals

Mankind Pharma

ISIN
INE634S01028
Instrument key
NSE_EQ|INE634S01028
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹2,665.00+36.00 · +1.37%
Day rangecircuit ₹2,398.50 – ₹2,931.50
2,620.20
2,669.90

as of 21/11/2026, 2:32:43 pm

Open
₹2,627.00
Day high
₹2,669.90
Day low
₹2,620.20
Prev. close
₹2,629.00
Volume
4.56 L
VWAP
₹2,646.06

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

5 years · weekly candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX
Change · 5Y
+91.11%
1,394.45 → 2,665.00
Period high
₹3,054.80
23/12/2024
Period low
₹1,242.00
22/5/2023
From high
-12.76%
+114.57% from low
Avg volume
29.59 L
54.74 Cr total
Volatility · ann.
27.8%
185 candles · 96 up / 89 down
16 Nov 2026O 2,625.60H 2,694.00L 2,584.00C 2,665.00Vol 17.59 L
SMA 20SMA 50Averages need 50 candles before they begin
Candle data185 rows of open, high, low, close and volumeShowHide
16 Nov 20262,625.602,694.002,584.002,665.00+1.50%110.0017.59 L
9 Nov 20262,600.002,705.002,585.202,640.00+1.54%119.8032.79 L
2 Nov 20262,505.302,593.602,457.902,582.90+3.10%135.7026.60 L
26 Oct 20262,223.702,549.002,215.002,492.80+12.10%334.0065.53 L
19 Oct 20262,264.102,348.502,196.102,212.60-2.27%152.4028.04 L
12 Oct 20262,368.502,426.802,268.702,275.50-3.93%158.1025.68 L
5 Oct 20262,533.102,539.302,342.002,368.50-6.50%197.3021.57 L
28 Sept 20262,474.902,559.002,430.302,535.00+2.43%128.7041.02 L
21 Sept 20262,312.702,504.602,303.002,474.90+7.01%201.6031.43 L
14 Sept 20262,280.002,329.502,242.102,300.70+0.91%87.4020.70 L

Historical price and volume data · Showing 1–10 of 185

1 / 19

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

48.54
Company
48.54
Sector
-45.02

Worse than sector by 208%

P/B

Price ÷ book value per share

6.25
Company
6.25
Sector
4.21

Worse than sector by 48%

ROA

Net income ÷ total assets

7.82%
Company
7.82%
Sector
1.19%

Better than sector by 557%

ROE

Net income ÷ shareholders' equity

12.76%
Company
12.76%
Sector
-0.4%

Better than sector by 3290%

ROCE

EBIT ÷ capital employed

14.68%
Company
14.68%
Sector
15.44%

Worse than sector by 5%

Quick Ratio

Liquid assets ÷ current liabilities

0.74
Company
0.74
Sector
4.8

Worse than sector by 85%

EV/EBITDA

Enterprise value ÷ EBITDA

26.33
Company
26.33
Sector
22.86

Worse than sector by 15%

04/Business

About the company

Sector: Pharmaceuticals

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, crop protection solutions, and veterinary care. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals and nutrients, derma, fertility, and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.

Sector market cap (INR)
₹1,09,870 Cr

reported in crore

Sector market cap (USD)
$12.21B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Standalone income statement

Annual figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Mar 2026
₹10,747 Cr
+7.46% vs Mar 2025
Net profit · Mar 2026
₹2,038 Cr
+14.09% vs Mar 2025
Operating margin
21.5%
was 21.5%
Revenue CAGR · 4p
9.0%
profit 17.7% · op 14.0%
Filed order
Revenue10,74710,0018,9008,290
Revenue growthreported7.5%12.4%7.4%—
Operating profit2,3152,1472,1851,563
Operating profit growthreported7.8%-1.8%39.8%—
Operating marginderived21.5%21.5%24.6%18.9%
Net profit2,0381,7861,8761,248
Net profit growthreported14.1%-4.8%50.3%—
Net marginderived19.0%17.9%21.1%15.1%
EPS — basic₹/share, annual49.3744.2246.8431.16

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue10,4219,5078,6298,127
Other Income326493271163
Total Revenue10,74710,0018,9008,290
Total Expenses8,3267,8546,7156,727
Profit Before Tax2,3152,1472,1851,563
Tax277422413315
Profit After Tax2,0381,7251,7731,248
EPS - Basic49.3744.2246.8431.16
EPS - Diluted49.3044.1346.7731.16

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Standalone balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹24,625 Cr
+0.68% YoY
Total liabilities
₹8,228 Cr
Net worth
₹16,397 Cr
Liabilities ÷ assets
33.4%
lower means a lighter balance sheet
Filed order
Total assets24,62524,45811,5169,371
Total liabilities8,22810,1361,8141,587
Net worthderived16,39714,3239,7037,784
Liabilities ÷ assetsderived33.4%41.4%15.7%16.9%
Asset growthderived0.7%112.4%22.9%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets20,43919,7385,8875,854
Current Assets4,1864,7215,6303,517
Total Assets24,62524,45811,5169,371
Current Liabilities5,4734,9591,6171,419
Net Current Asset-1,287-2384,0132,098
Non-Current Liabilities2,7555,177197168
Equity Capital16,39714,3239,7037,784
Total Equity & Liabilities24,62524,45811,5169,371

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Standalone cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹2,752 Cr
+17.10% YoY
Investing
-₹388 Cr
Financing
-₹2,477 Cr
Free cash flow
₹2,364 Cr
operating + investing
Filed order
Operating activities2,7522,3501,7361,799
Operating changereported17.1%35.4%-3.5%—
Investing activities-388-12,114-1,665-1,041
Investing changereported96.8%-627.5%-60.0%—
Financing activities-2,4779,817-5-710
Financing changereported-125.2%207637.0%99.3%—
Net cash flowderived-113526648
Free cash flowoperating + investing2,364-9,76471758

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax2,3152,2312,3261,563
Income before WC changes3,0462,7032,4901,790
Change in Assets-139-186-584428
Change in Liabilities319305250-134
Change in WC180118-333294
Cash flow from Operations2,7522,3501,7361,799
Cash flow from Investing-388-12,114-1,665-1,041
Cash flow from Financing-2,4779,817-5-710
Total Cash Flow-113526648
Cash (Start of the year)20121214586
Cash (End of the year)88201212134

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
72.62%
-0.01 pts QoQ
FII
9.37%
-0.08 pts QoQ
DII (other)
4.25%
-0.27 pts QoQ
Mutual funds
11.31%
+0.44 pts QoQ
Retail & others
2.45%
-0.08 pts QoQ
Filed order
Promoters72.6%72.6%72.7%72.7%
FII9.4%9.4%10.2%11.3%
DII (other)4.3%4.5%4.1%4.0%
Mutual funds11.3%10.9%10.4%9.3%
Retail & others2.5%2.5%2.6%2.8%
Promoters — QoQ changepts, derived-0.0%-0.0%0.0%—
FII — QoQ changepts, derived-0.1%-0.8%-1.1%—
DII (other) — QoQ changepts, derived-0.3%0.4%0.1%—
Mutual funds — QoQ changepts, derived0.4%0.5%1.1%—
Retail & others — QoQ changepts, derived-0.1%-0.1%-0.1%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

No corporate actions on record

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

No news in the last seven days

Company news is available for a rolling one-week window.